278 related articles for article (PubMed ID: 16531032)
1. Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents.
Niederman MS; Anzueto A; Sethi S; Choudhri S; Kureishi A; Haverstock D; Perroncel R
Respir Med; 2006 Oct; 100(10):1781-90. PubMed ID: 16531032
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
DeAbate CA; Mathew CP; Warner JH; Heyd A; Church D
Respir Med; 2000 Nov; 94(11):1029-37. PubMed ID: 11127487
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.
Zervos M; Martinez FJ; Amsden GW; Rothermel CD; Treadway G
Int J Antimicrob Agents; 2007 Jan; 29(1):56-61. PubMed ID: 17189096
[TBL] [Abstract][Full Text] [Related]
4. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
Starakis I; Gogos CA; Bassaris H
Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
6. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort.
Urueta-Robledo J; Ariza H; Jardim JR; Caballero A; García-Calderón A; Amábile-Cuevas CF; Hernández-Oliva G; Vivar-Orozco R;
Respir Med; 2006 Sep; 100(9):1504-11. PubMed ID: 16504492
[TBL] [Abstract][Full Text] [Related]
7. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis.
Wilson R; Allegra L; Huchon G; Izquierdo JL; Jones P; Schaberg T; Sagnier PP;
Chest; 2004 Mar; 125(3):953-64. PubMed ID: 15006954
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis.
Gotfried M; Notario G; Spiller J; Palmer R; Busman T
Curr Med Res Opin; 2005 Feb; 21(2):245-54. PubMed ID: 15801995
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J
Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
[TBL] [Abstract][Full Text] [Related]
10. Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice.
Schaberg T; Möller M; File T; Stauch K; Landen H
Clin Drug Investig; 2006; 26(12):733-44. PubMed ID: 17274680
[TBL] [Abstract][Full Text] [Related]
11. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
12. Prospective observational study of patient-reported outcomes for azithromycin versus usual care in the treatment of bacterial acute exacerbation of chronic bronchitis.
Milstone A; Patsimas J; Farzan D; Castaldo R; Singh H; Feurer I; Harnett J; Luke DR;
Clin Ther; 2005 Jun; 27(6):926-39. PubMed ID: 16117993
[TBL] [Abstract][Full Text] [Related]
13. Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis.
Ohnsman C; Ritterband D; O'Brien T; Girgis D; Kabat A
Curr Med Res Opin; 2007 Sep; 23(9):2241-9. PubMed ID: 17688706
[TBL] [Abstract][Full Text] [Related]
14. Short-course therapy of acute bacterial exacerbation of chronic bronchitis: a double-blind, randomized, multicenter comparison of extended-release versus immediate-release clarithromycin.
Nalepa P; Dobryniewska M; Busman T; Notario G
Curr Med Res Opin; 2003; 19(5):411-20. PubMed ID: 13678478
[TBL] [Abstract][Full Text] [Related]
15. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.
Lipsky BA; Giordano P; Choudhri S; Song J
J Antimicrob Chemother; 2007 Aug; 60(2):370-6. PubMed ID: 17553812
[TBL] [Abstract][Full Text] [Related]
16. Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis.
Arrieta JR; Galgano AS; Sakano E; Fonseca X; Amábile-Cuevas CF; Hernández-Oliva G; Vivar R; González G; Torres A;
Am J Otolaryngol; 2007; 28(2):78-82. PubMed ID: 17362810
[TBL] [Abstract][Full Text] [Related]
17. Discrepancy between antibiotics administered in acute exacerbations of chronic bronchitis and susceptibility of isolated pathogens in respiratory samples: multicentre study in the primary care setting.
Querol-Ribelles JM; Molina J; Naberan K; Esteban E; Herreras A; Garcia-de-Lomas J
Int J Antimicrob Agents; 2006 Nov; 28(5):472-6. PubMed ID: 17046209
[TBL] [Abstract][Full Text] [Related]
18. Macrolide therapy of group A streptococcal pharyngitis: 10 days of macrolide therapy (clarithromycin) is more effective in streptococcal eradication than 5 days (azithromycin).
Kaplan EL; Gooch III WM; Notario GF; Craft JC
Clin Infect Dis; 2001 Jun; 32(12):1798-802. PubMed ID: 11360224
[TBL] [Abstract][Full Text] [Related]
19. Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis.
Hadley JA; Mösges R; Desrosiers M; Haverstock D; van Veenhuyzen D; Herman-Gnjidic Z
Laryngoscope; 2010 May; 120(5):1057-62. PubMed ID: 20422704
[TBL] [Abstract][Full Text] [Related]
20. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
Solomkin J; Zhao YP; Ma EL; Chen MJ; Hampel B;
Int J Antimicrob Agents; 2009 Nov; 34(5):439-45. PubMed ID: 19692210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
